Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003650225 | SCV004520547 | pathogenic | Peroxisome biogenesis disorder, complementation group 7 | 2023-04-07 | criteria provided, single submitter | clinical testing | This sequence change results in a frameshift in the PEX10 gene (p.Pro307Cysfs*53). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 40 amino acid(s) of the PEX10 protein and extend the protein by 12 additional amino acid residues. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with PEX10-related conditions. This variant disrupts a region of the PEX10 protein in which other variant(s) (p.Arg331Gln) have been determined to be pathogenic (PMID: 20695019, 27230853). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV004573261 | SCV005055243 | likely pathogenic | Peroxisome biogenesis disorder 6A (Zellweger) | 2023-11-26 | criteria provided, single submitter | clinical testing |